Trial Profile
A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2021
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Auranofin (Primary) ; Captopril (Primary) ; Celecoxib (Primary) ; Disulfiram (Primary) ; Itraconazole (Primary) ; Minocycline (Primary) ; Ritonavir (Primary) ; Sertraline (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 24 Dec 2020 Status changed from recruiting to completed.
- 09 May 2017 New trial record